Prevalence of GB virus-C/hepatitis G virus infection in patients with cryptogenic chronic liver disease and in patients with primary biliary cirrhosis or Wilson's disease

Alessandro Tagger, Maria Lisa Ribero, Alberto Larghi, Francesco Donate, Massimo Zuin, Roberta Chiesa, M. Ü Giampiero Benetti, Giuliano Ramella, Mauro Borzio, Mauro Podda

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To assess the role of hepatitis G virus (HGV) in cryptogenic chronic liver disease (CLD), we investigated the prevalence of HGV RNA among patients with cryptogenic CLD, patients with nonviral CLD (primary biliary cirrhosis [PBC] and Wilson's disease [WD]) and subjects without clinically evident liver disease (controls). Methods: Ninety patients with cryptogenic CLD (43 with chronic hepatitis, 20 with cirrhosis, and 27 with hepatocellular carcinoma [HCC]), 143 patients with PBC, 22 patients with WD, and 134 controls were recruited. HGV RNA was detected by reverse transcription- polymerase chain reaction (RT-PCR) and antibodies against HGV E2 protein (anti-E2) by an immunoassay test. Results: HGV RNA was detected in 7.8% of patients with cryptogenic CLD (chronic hepatitis, 9.3%; cirrhosis, 5.0%; HCC, 7.4%), in 2.4% of patients with PBC or WD, and in 2.2% of controls. As a consequence, a positive association of HGV infection with cryptogenic CLD was found (odds ratio, 3.1; 95% confidence interval [CI], 1.0-9.7; p = 0.05). No difference was observed between HGV RNA-positive and -negative patients by age, sex, histology, or liver function tests. Anti-E2 prevalence did not differ between patients with cryptogenic CLD (26.5%), patients with PBC (28.1%), and controls (22.1%). Transfusion history was associated with HGV RNA but not with anti-E2 seropositivity. Conclusions: Although an association was found between cryptogenic CLD and HGV infection, the role of the virus seems far from important, the proportion of cryptogenic CLD attributable to it being only 5.2%.

Original languageEnglish
Pages (from-to)484-488
Number of pages5
JournalAmerican Journal of Gastroenterology
Volume94
Issue number2
DOIs
Publication statusPublished - Feb 1999

Fingerprint

GB virus C
Hepatolenticular Degeneration
Biliary Liver Cirrhosis
Virus Diseases
Liver Diseases
Chronic Disease
RNA
Chronic Hepatitis
Hepatocellular Carcinoma
Fibrosis
Liver Function Tests
Immunoassay
Reverse Transcription
Histology
History
Odds Ratio

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Prevalence of GB virus-C/hepatitis G virus infection in patients with cryptogenic chronic liver disease and in patients with primary biliary cirrhosis or Wilson's disease. / Tagger, Alessandro; Ribero, Maria Lisa; Larghi, Alberto; Donate, Francesco; Zuin, Massimo; Chiesa, Roberta; Giampiero Benetti, M. Ü; Ramella, Giuliano; Borzio, Mauro; Podda, Mauro.

In: American Journal of Gastroenterology, Vol. 94, No. 2, 02.1999, p. 484-488.

Research output: Contribution to journalArticle

Tagger, Alessandro ; Ribero, Maria Lisa ; Larghi, Alberto ; Donate, Francesco ; Zuin, Massimo ; Chiesa, Roberta ; Giampiero Benetti, M. Ü ; Ramella, Giuliano ; Borzio, Mauro ; Podda, Mauro. / Prevalence of GB virus-C/hepatitis G virus infection in patients with cryptogenic chronic liver disease and in patients with primary biliary cirrhosis or Wilson's disease. In: American Journal of Gastroenterology. 1999 ; Vol. 94, No. 2. pp. 484-488.
@article{16a5c86f7da54ee0ac0565bb31dcd5fd,
title = "Prevalence of GB virus-C/hepatitis G virus infection in patients with cryptogenic chronic liver disease and in patients with primary biliary cirrhosis or Wilson's disease",
abstract = "Objective: To assess the role of hepatitis G virus (HGV) in cryptogenic chronic liver disease (CLD), we investigated the prevalence of HGV RNA among patients with cryptogenic CLD, patients with nonviral CLD (primary biliary cirrhosis [PBC] and Wilson's disease [WD]) and subjects without clinically evident liver disease (controls). Methods: Ninety patients with cryptogenic CLD (43 with chronic hepatitis, 20 with cirrhosis, and 27 with hepatocellular carcinoma [HCC]), 143 patients with PBC, 22 patients with WD, and 134 controls were recruited. HGV RNA was detected by reverse transcription- polymerase chain reaction (RT-PCR) and antibodies against HGV E2 protein (anti-E2) by an immunoassay test. Results: HGV RNA was detected in 7.8{\%} of patients with cryptogenic CLD (chronic hepatitis, 9.3{\%}; cirrhosis, 5.0{\%}; HCC, 7.4{\%}), in 2.4{\%} of patients with PBC or WD, and in 2.2{\%} of controls. As a consequence, a positive association of HGV infection with cryptogenic CLD was found (odds ratio, 3.1; 95{\%} confidence interval [CI], 1.0-9.7; p = 0.05). No difference was observed between HGV RNA-positive and -negative patients by age, sex, histology, or liver function tests. Anti-E2 prevalence did not differ between patients with cryptogenic CLD (26.5{\%}), patients with PBC (28.1{\%}), and controls (22.1{\%}). Transfusion history was associated with HGV RNA but not with anti-E2 seropositivity. Conclusions: Although an association was found between cryptogenic CLD and HGV infection, the role of the virus seems far from important, the proportion of cryptogenic CLD attributable to it being only 5.2{\%}.",
author = "Alessandro Tagger and Ribero, {Maria Lisa} and Alberto Larghi and Francesco Donate and Massimo Zuin and Roberta Chiesa and {Giampiero Benetti}, {M. {\"U}} and Giuliano Ramella and Mauro Borzio and Mauro Podda",
year = "1999",
month = "2",
doi = "10.1111/j.1572-0241.1999.882_k.x",
language = "English",
volume = "94",
pages = "484--488",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Prevalence of GB virus-C/hepatitis G virus infection in patients with cryptogenic chronic liver disease and in patients with primary biliary cirrhosis or Wilson's disease

AU - Tagger, Alessandro

AU - Ribero, Maria Lisa

AU - Larghi, Alberto

AU - Donate, Francesco

AU - Zuin, Massimo

AU - Chiesa, Roberta

AU - Giampiero Benetti, M. Ü

AU - Ramella, Giuliano

AU - Borzio, Mauro

AU - Podda, Mauro

PY - 1999/2

Y1 - 1999/2

N2 - Objective: To assess the role of hepatitis G virus (HGV) in cryptogenic chronic liver disease (CLD), we investigated the prevalence of HGV RNA among patients with cryptogenic CLD, patients with nonviral CLD (primary biliary cirrhosis [PBC] and Wilson's disease [WD]) and subjects without clinically evident liver disease (controls). Methods: Ninety patients with cryptogenic CLD (43 with chronic hepatitis, 20 with cirrhosis, and 27 with hepatocellular carcinoma [HCC]), 143 patients with PBC, 22 patients with WD, and 134 controls were recruited. HGV RNA was detected by reverse transcription- polymerase chain reaction (RT-PCR) and antibodies against HGV E2 protein (anti-E2) by an immunoassay test. Results: HGV RNA was detected in 7.8% of patients with cryptogenic CLD (chronic hepatitis, 9.3%; cirrhosis, 5.0%; HCC, 7.4%), in 2.4% of patients with PBC or WD, and in 2.2% of controls. As a consequence, a positive association of HGV infection with cryptogenic CLD was found (odds ratio, 3.1; 95% confidence interval [CI], 1.0-9.7; p = 0.05). No difference was observed between HGV RNA-positive and -negative patients by age, sex, histology, or liver function tests. Anti-E2 prevalence did not differ between patients with cryptogenic CLD (26.5%), patients with PBC (28.1%), and controls (22.1%). Transfusion history was associated with HGV RNA but not with anti-E2 seropositivity. Conclusions: Although an association was found between cryptogenic CLD and HGV infection, the role of the virus seems far from important, the proportion of cryptogenic CLD attributable to it being only 5.2%.

AB - Objective: To assess the role of hepatitis G virus (HGV) in cryptogenic chronic liver disease (CLD), we investigated the prevalence of HGV RNA among patients with cryptogenic CLD, patients with nonviral CLD (primary biliary cirrhosis [PBC] and Wilson's disease [WD]) and subjects without clinically evident liver disease (controls). Methods: Ninety patients with cryptogenic CLD (43 with chronic hepatitis, 20 with cirrhosis, and 27 with hepatocellular carcinoma [HCC]), 143 patients with PBC, 22 patients with WD, and 134 controls were recruited. HGV RNA was detected by reverse transcription- polymerase chain reaction (RT-PCR) and antibodies against HGV E2 protein (anti-E2) by an immunoassay test. Results: HGV RNA was detected in 7.8% of patients with cryptogenic CLD (chronic hepatitis, 9.3%; cirrhosis, 5.0%; HCC, 7.4%), in 2.4% of patients with PBC or WD, and in 2.2% of controls. As a consequence, a positive association of HGV infection with cryptogenic CLD was found (odds ratio, 3.1; 95% confidence interval [CI], 1.0-9.7; p = 0.05). No difference was observed between HGV RNA-positive and -negative patients by age, sex, histology, or liver function tests. Anti-E2 prevalence did not differ between patients with cryptogenic CLD (26.5%), patients with PBC (28.1%), and controls (22.1%). Transfusion history was associated with HGV RNA but not with anti-E2 seropositivity. Conclusions: Although an association was found between cryptogenic CLD and HGV infection, the role of the virus seems far from important, the proportion of cryptogenic CLD attributable to it being only 5.2%.

UR - http://www.scopus.com/inward/record.url?scp=0033083024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033083024&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.1999.882_k.x

DO - 10.1111/j.1572-0241.1999.882_k.x

M3 - Article

C2 - 10022651

AN - SCOPUS:0033083024

VL - 94

SP - 484

EP - 488

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 2

ER -